Merocar500 mg/vial

Merocar 500 mg/vial is a broad-spectrum injectable carbapenem antibiotic prescribed for adults and children to treat serious bacterial infections caused by susceptible single or mixed (polymicrobial) organisms. Because of its potent activity against both Gram-positive and Gram-negative pathogens, it is often reserved for moderate to severe infections, including those acquired in hospital settings.

Meropenem injection is commonly indicated for:

• Community-acquired pneumonia and nosocomial (hospital-acquired) pneumonia
• Urinary tract infections (UTIs), including complicated cases
• Intra-abdominal infections such as peritonitis
• Gynaecological infections, including endometritis and pelvic inflammatory disease (PID)
• Skin and skin structure infections
• Bacterial meningitis
• Septicaemia (bloodstream infections)
• Pulmonary infections associated with cystic fibrosis
• Empiric (presumptive) treatment of suspected infections in patients with febrile neutropenia

Treatment should always be guided by culture and sensitivity testing whenever possible, along with local antimicrobial resistance patterns, to ensure appropriate and effective use.

Merocar 500 mg/vial belongs to the therapeutic class of other beta-lactam antibiotics, specifically the carbapenem subgroup, which is known for its broad-spectrum activity and stability against many bacterial beta-lactamase enzymes.

Meropenem is a synthetic carbapenem-class antibiotic formulated for parenteral (intravenous) administration. It exerts a bactericidal effect by disrupting bacterial cell wall synthesis, ultimately leading to cell lysis and death of the pathogen.

Meropenem readily penetrates the outer membrane of most Gram-negative and Gram-positive bacteria. It demonstrates a high degree of stability against hydrolysis by most serine beta-lactamases, including penicillinases, cephalosporinases, and many extended-spectrum beta-lactamases (ESBLs). This stability, combined with its strong binding affinity for Penicillin-Binding Proteins (PBPs) — particularly PBP2 and PBP3 — allows meropenem to exert potent bactericidal activity against a wide range of aerobic and anaerobic organisms.

Its broad spectrum of activity covers many clinically important pathogens, making it a valuable option for empiric therapy in severe or life-threatening infections, especially where resistant organisms are suspected.

Meropenem is administered exclusively by the intravenous route and must not be given intramuscularly. It can be given in two ways:

• Intravenous infusion: Administered over approximately 15 to 30 minutes
• Intravenous bolus injection: Administered as 5 to 20 mL over approximately 3 to 5 minutes

The choice of administration method depends on the clinical setting, dose required, and patient tolerance. Reconstituted solutions should be inspected visually for particulate matter and discoloration before use.

• Probenecid: Competes with meropenem for active renal tubular secretion, which inhibits meropenem's excretion, increases its plasma concentration, and prolongs its elimination half-life. Concurrent use with probenecid is generally not recommended unless clinically justified.
• Valproic acid / Sodium valproate: Meropenem can significantly reduce serum valproic acid levels, sometimes to sub-therapeutic concentrations, which may increase the risk of breakthrough seizures in patients being treated for epilepsy. This combination should generally be avoided; alternative antibacterial or anticonvulsant therapy should be considered.

Patients on concurrent medications should have their treatment regimen reviewed by a physician before starting meropenem therapy.

Meropenem is generally well tolerated. However, as with all antibiotics, some patients may experience adverse effects, including:

• Inflammation, thrombophlebitis, and pain at the injection site
• Skin reactions such as rash, pruritus (itching), and urticaria (hives)
• Gastrointestinal effects, including abdominal pain, nausea, vomiting, and diarrhea
• Headache

Patients should seek immediate medical attention if they experience signs of a serious allergic reaction, such as difficulty breathing, swelling of the face or throat, or severe skin reactions.

Meropenem falls under Pregnancy Category B. Adequate and well-controlled studies in pregnant women are lacking, so meropenem should be used during pregnancy only when clearly needed and when the potential benefit justifies the potential risk to the fetus.

Since many drugs are excreted in human breast milk, caution should be exercised when meropenem is administered to a breastfeeding woman. Consultation with a physician is recommended before use during breastfeeding.

If a patient develops an allergic reaction while receiving meropenem, the drug should be discontinued immediately and appropriate supportive treatment initiated.

Meropenem should be used with careful monitoring of liver function tests, including transaminase and bilirubin levels, in patients with pre-existing hepatic disease.

As with other broad-spectrum antibiotics, prolonged use may result in overgrowth of non-susceptible organisms, including fungal superinfection. Clinical monitoring throughout the course of therapy is advised.

Accidental overdose may occur during treatment, particularly in patients with renal impairment. Management of overdose is primarily symptomatic and supportive.

In patients with normal renal function, meropenem is rapidly eliminated by the kidneys. In patients with renal impairment, hemodialysis effectively removes meropenem and its inactive metabolite from the bloodstream, and may be used as part of overdose management.

Store the vial in a cool, dry place below 30°C, protected from light and moisture. Keep out of the reach and sight of children. Discard any reconstituted solution that is not used within the recommended timeframe.

Renal Impairment

Dosage should be reduced in patients with a creatinine clearance of less than 51 mL/min, based on standard dose-adjustment guidelines for carbapenems.

Hepatic Impairment

No dosage adjustment is necessary in patients with impaired liver function. Patients undergoing hemodialysis should receive their meropenem dose after the dialysis session is completed.

Elderly Patients

No dosage adjustment is required in elderly patients unless creatinine clearance falls below 51 mL/min, in which case renal-based dose adjustment should be applied.

Use in Children

The efficacy and safety of meropenem in infants under 3 months of age have not been established.

Intravenous Bolus Administration

Reconstitute meropenem (500 mg or 1 g vial) with sterile water for injection. Shake well to dissolve, producing a solution that is clear and colorless to pale yellow.

Intravenous Infusion Administration

Meropenem for intravenous infusion may be directly reconstituted with a compatible infusion fluid and then further diluted with 50 to 200 mL of a compatible infusion fluid as needed.

Compatible Infusion Fluids

• 0.9% sodium chloride intravenous infusion
• 5% or 10% glucose intravenous infusion
• 5% glucose intravenous infusion with 0.02% sodium bicarbonate
• 5% glucose and 0.9% sodium chloride intravenous infusion
• 5% glucose with 0.225% sodium chloride intravenous infusion
• 5% glucose with 0.15% potassium chloride intravenous infusion
• 2.5% and 10% mannitol intravenous infusion
• Normosol-M in 5% glucose intravenous infusion

Use of freshly reconstituted solution is strongly recommended. If storage is necessary, the solution retains potency for up to 3 hours at temperatures up to 25°C, or up to 13 hours when refrigerated at up to 5°C.